Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study.
Saved in:
| Title: | Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study. |
|---|---|
| Authors: | Peña-Enríquez R; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain., Bermejo B; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Clínico Universitario de Valencia, Valencia, Spain.; Instituto de Investigación Sanitaria INCLIVA, Universidad de Valencia, Valencia, Spain., Pollán M; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Department of Epidemiology of Chronic Diseases, National Center for Epidemiology, ISCIII, Madrid, Spain.; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP-ISCIII), Madrid, Spain., Díaz-Chacón A; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain., Jerez Gilarranz Y; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Madrid, Spain., Ponce Lorenzo JJ; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Oncology Department, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain., Fernández Aramburo A; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital General Universitario de Albacete, Albacete, Spain., Cantos Sánchez de Ibargüen B; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Department of Medical Oncology, Hospital Puerta de Hierro, Majadahonda, Madrid, Spain., Santaballa Bertrán A; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Medical Oncology Department, La Fe Health Research Institute (IIS La Fe), La Fe University, Valencia, Spain., Galve-Calvo E; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Medical Oncology Service, Hospital Universitario Basurto (OSI Bilbao-Basurto), Bilbao, Spain., Jiménez-Arranz Á; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain., Fernández Y; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Medical Oncology, Hospital Central de Asturias, Oviedo, Spain., Pérez ME; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Medical Oncology Department, Hospital Universitario A Coruña (HUAC), A Coruña, Spain., De La Cruz S; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Complejo Hospitalario de Navarra, Pamplona, Spain., Anton-Torres A; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Instituto Investigación Sanitaria Aragón, Hospital Universitario Miguel Servet, Universidad de Zaragoza, Zaragoza, Spain., Moreno F; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Medical Oncology Department, Hospital Clínico San Carlos, Madrid, Spain., Vidal-Losada MJ; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Clinic de Barcelona, Barcelona, Spain., López-Ceballos MH; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital San Pedro de Alcántara, Cáceres, Spain., Blancas I; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Universitario Clínico San Cecilio, Granada, Spain.; Department of Medicine, University of Granada, Granada, Spain.; Instituto de Investigacion Biosanitaria de Granada (ibs.Granada), Granada, Spain., Echarri MJ; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Hospital Universitario Severo Ochoa, Leganes, Spain., Rincón R; GEICAM, Spanish Breast Cancer Group, Madrid, Spain., Caballero R; GEICAM, Spanish Breast Cancer Group, Madrid, Spain., Guerrero-Zotano Á; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.; Instituto Valenciano de Oncología (IVO), Valencia, Spain., Guil-Luna S; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain. v22gulus@uco.es.; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain. v22gulus@uco.es.; Department of Anatomy and Comparative Pathology and Toxicology, University of Cordoba, Córdoba, España. v22gulus@uco.es., de la Haba-Rodríguez J; Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)-Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain. juahaba@gmail.com.; GEICAM, Spanish Breast Cancer Group, Madrid, Spain. juahaba@gmail.com.; Oncology Biomedical Research National Network (CIBERONC-ISCIII), Madrid, Spain. juahaba@gmail.com. |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2025 Feb 08; Vol. 11 (1), pp. 12. Date of Electronic Publication: 2025 Feb 08. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
